Clarke, N. W., Ali, A., Ingleby, F. C., Hoyle, A., Amos, C. L., Attard, G., Brawley, C. D., Calvert, J., Chowdhury, S., Cook, A., Cross, W., Dearnaley, D. P., Douis, H., Gilbert, D., Gillessen, S., Jones, R. J., Langley, R. E., MacNair, A., Malik, Z., Mason, M. D., Matheson, D., Millman, R., Parker, C. C., Ritchie, A. W. S., Rush, H., Russell, J. M., Brown, J., Beesley, S., Birtle, A., Capaldi, L., Gale, J., Gibbs, S., Lydon, A., Nikapota, A., Omlin, A., O'Sullivan, J. M., Parikh, O., Protheroe, A., Rudman, S., Srihari, N. N., Simms, M., Tanguay, J. S., Tolan, S., Wagstaff, J., Wallace, J., Wylie, J., Zarkar, A., Sydes, M. R., Parmar, M. K. B., & James, N. D. (2019). addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. Annals of oncology, 30, 1992–2003. http://access.bl.uk/ark:/81055/vdc_100099399783.0x000030